Lilian Mazza Barbosa

TL;DR: In this paper, the authors compared the efficacy and safety of therapeutic versus prophylactic anticoagulation in patients hospitalised with COVID-19 in 31 sites in Brazil, and found that in the case of stable patients, in-hospital oral rivaroxaban (20 mg or 15 mg daily) or initial subcutaneous enoxaparin (1 mg/kg twice per day) or intravenous unfractionated heparin (to achieve a 0·3-0·7 IU/mL anti-Xa concentration) for clinically unstable patients, followed

TL;DR: A multifaceted and multilevel educational intervention, aimed to improve use of oral anticoagulation in patients with atrial fibrillation and at risk for stroke, resulted in a significant increase in the proportion of patients treated with oral antICOagulants.

TL;DR: Among patients with ACS and planned invasive management with PCI, periprocedural loading doses of atorvastatin did not reduce the rate of MACE at 30 days, and these findings do not support the routine use of loading doses in patients with acute coronary syndrome and intended invasive management.

TL;DR: In patients with ACS undergoing PCI, periprocedural loading doses of atorvastatin appeared to reduce the rate of MACE at 30 days, most clearly in patients with ST-segment elevation myocardial infarction.

TL;DR: Aplicabilidade clinica diaria de inovacoes e evidencias cientificas tem oferecido relevante melhoria da morbidade e da mortalidade das mais distintas doencas, oferecendo tambem melhor expectativa em qualidade de vida as discussed by the authors.